ppat.1006182.g002.tif (2.3 MB)
The long Heavy Chain Determinant Region 3 (HCDR3) antibodies that neutralize virus bind the CD4 binding site (CD4 bs).
figure
posted on 2017-02-24, 19:50 authored by David Easterhoff, M. Anthony Moody, Daniela Fera, Hao Cheng, Margaret Ackerman, Kevin Wiehe, Kevin O. Saunders, Justin Pollara, Nathan Vandergrift, Rob Parks, Jerome Kim, Nelson L. Michael, Robert J. O’Connell, Jean-Louis Excler, Merlin L. Robb, Sandhya Vasan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, Sorachai Nitayaphan, Faruk Sinangil, James Tartaglia, Sanjay Phogat, Thomas B. Kepler, S. Munir Alam, Hua-Xin Liao, Guido Ferrari, Michael S. Seaman, David C. Montefiori, Georgia D. Tomaras, Stephen C. Harrison, Barton F. HaynesPurified recombinant monoclonal antibodies (mAbs) were assayed by ELISA for (A) blocking the binding of soluble CD4 to AE.A244gp120, and (B) sensitivity to the CD4 binding site mutations Δ371I/P363N, D368R, N276A, and T278A in the AE.A244gp120 protein. (C) Epitope mapping of mAbs on yeast displayed YU2gp120 with point mutations within the inner domain, outer domain and CD4 binding site. (D) Assaying the long HCDR3 CD4 bs antibodies for HIV-1 neutralization in the TZM-bl neutralization assay.
History
Usage metrics
Categories
Keywords
envelope CD 4 binding sitevaccine trialvaccine Env AE.A 244 gp 120AIDSVAXEnv-specific post-RV 144gp 120 vaccinememory B cell V H mutation frequenciesRV 305 HIVRV 305 trialantibody1VRV 305HIV -1-uninfected RV 144 vaccine recipientsRV 144 vaccineesCRF 01 AE tier 2plasma bnAb activityB cell repertoiresnear-native gp 140 trimersHIV envelope CD 4 binding site antibodiesB cell clonal lineage membersneutralizing B cell clonal lineagesCNE 8. Electron microscopyplacebo-controlled randomized double-blinded studycanary pox vectortier 2 HIVALVAC-HIVRV 144 HIVHCDRNCT
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC